Takeda Pharmaceutical (TAK) earnings
Takeda Pharmaceutical (TAK) reported net income of -¥152.39B in fiscal 2026 (the year ended March 31, 2026). In fiscal 2025 the figure was ¥107.93B. Figures as of 18 Nov 2026, 05:36 UTC, from Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2026
- -¥152.39B
- Highest on record
- ¥317.02Bfiscal 2023
- Lowest on record
- -¥152.39Bfiscal 2026
- Fiscal years on record
- 42023–2026
Figures as of . Statements from Yahoo Finance. Amounts are in JPY. Figures, not advice.
Takeda Pharmaceutical earnings, in more detail
Across the 4 fiscal years on record (2023–2026), the highest was ¥317.02B in fiscal 2023 and the lowest -¥152.39B in fiscal 2026.
Earnings (net income) by fiscal year
Takeda Pharmaceutical earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2026 | -¥152.39B | 241.2% down | |
| 2025 | ¥107.93B | 25.1% down | |
| 2024 | ¥144.07B | 54.6% down | |
| 2023 | ¥317.02B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Takeda Pharmaceutical, figure by figure
- Takeda Pharmaceutical market cap
- Takeda Pharmaceutical revenue
- Takeda Pharmaceutical earnings per share (EPS)
- Takeda Pharmaceutical P/E ratio
- Takeda Pharmaceutical P/S ratio
- Takeda Pharmaceutical P/B ratio
- Takeda Pharmaceutical free cash flow
- Takeda Pharmaceutical operating margin
- Takeda Pharmaceutical dividend
- Takeda Pharmaceutical shares outstanding
- Takeda Pharmaceutical total debt
- Takeda Pharmaceutical cash on hand
- Takeda Pharmaceutical total assets
- Takeda Pharmaceutical return on equity (ROE)
- Takeda Pharmaceutical return on invested capital (ROIC)
Takeda Pharmaceutical (TAK) overview: price, valuation and scorecardAll health care companies by market value
Takeda Pharmaceutical earnings: questions and answers
What is Takeda Pharmaceutical's net income?
Takeda Pharmaceutical (TAK) reported net income of -¥152.39B in fiscal 2026 (the year ended March 31, 2026). In fiscal 2025 the figure was ¥107.93B.
What are the highest and lowest net income figures on record for Takeda Pharmaceutical?
Across the 4 fiscal years on record (2023–2026), the highest was ¥317.02B in fiscal 2023 and the lowest -¥152.39B in fiscal 2026.
How is Takeda Pharmaceutical's net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Takeda Pharmaceutical (TAK) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/TAK/earnings
Underlying data: Yahoo Finance.